Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy

Abstract excerpt

Sir, A maximal suppression of HIV-1 replication before delivery is a main objective of anti-HIV treatment in pregnancy.1 Although there is limited information on the use of the integrase inhibitor raltegravir in pregnancy, this drug has been shown to induce a rapid HIV-RNA decline in other studies2 and could therefore be considered in cases characterized by limited time available for intervention. A woman...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to HIV/AIDS drug development and treatment
• Share to HIV Research and Treatment
• Share to Pneumocystis jirovecii pneumonia detection and treatment